Previous close | 23.86 |
Open | 24.14 |
Bid | 24.01 x 100 |
Ask | 24.07 x 600 |
Day's range | 23.92 - 24.48 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 2,062,603 |
Market cap | 4.07B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 7.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.